https://www.nasdaq.com/press-release/recap-and-update-of-positive-data-from-three-presentations-in-patients-with-tp53
https://www.nasdaq.com/press-release/aprea-therapeutics-presents-primary-analysis-from-phase-2-trial-of-eprenetapopt
https://www.nasdaq.com/press-release/aprea-therapeutics-announces-removal-of-fda-clinical-hold-on-eprenetapopt-in-lymphoid
https://www.nasdaq.com/press-release/aprea-therapeutics-reports-third-quarter-2021-financial-results-and-provides-update
https://www.nasdaq.com/press-release/aprea-therapeutics-to-present-data-from-clinical-trials-evaluating-eprenetapopt-at
https://www.nasdaq.com/press-release/aprea-therapeutics-presents-data-from-phase-1-2-trial-of-eprenetapopt-apr-246-in
https://www.nasdaq.com/press-release/aprea-therapeutics-to-present-data-from-phase-1-2-trial-of-eprenetapopt-in-advanced
https://www.nasdaq.com/press-release/aprea-therapeutics-reports-second-quarter-2021-financial-results-and-provides-update
https://www.nasdaq.com/press-release/aprea-therapeutics-announces-clinical-hold-on-lymphoid-malignancy-program-2021-08-12
https://www.nasdaq.com/press-release/aprea-therapeutics-announces-a-partial-clinical-hold-on-myeloid-malignancy-programs
https://www.nasdaq.com/press-release/aprea-therapeutics-announces-positive-results-from-phase-2-trial-of-eprenetapopt
https://www.nasdaq.com/press-release/aprea-therapeutics-announces-phase-1-2-trial-of-eprenetapopt-venetoclax-azacitidine
https://www.nasdaq.com/press-release/aprea-therapeutics-to-participate-in-the-2021-oppenheimer-rare-orphan-disease-summit
https://www.nasdaq.com/press-release/aprea-therapeutics-to-participate-in-the-2021-rbc-capital-markets-global-healthcare
https://www.nasdaq.com/press-release/aprea-therapeutics-reports-first-quarter-2021-financial-results-and-provides-update
https://www.nasdaq.com/press-release/aprea-therapeutics-to-host-virtual-rd-day-on-april-22-2021-2021-04-16
https://www.nasdaq.com/press-release/aprea-therapeutics-receives-fda-orphan-drug-designation-for-eprenetapopt-for-the
https://www.nasdaq.com/press-release/aprea-therapeutics-reports-fourth-quarter-and-full-year-2020-financial-results-and
https://www.nasdaq.com/press-release/aprea-therapeutics-to-present-at-the-39th-annual-j.p.-morgan-healthcare-conference-on
https://www.nasdaq.com/press-release/aprea-therapeutics-announces-results-of-primary-endpoint-from-phase-3-trial-of
https://www.nasdaq.com/press-release/aprea-therapeutics-receives-fda-fast-track-designation-for-eprenetapopt-in-the
https://www.nasdaq.com/press-release/aprea-therapeutics-to-participate-in-the-32nd-annual-piper-sandler-healthcare
https://www.nasdaq.com/press-release/aprea-therapeutics-reports-third-quarter-2020-financial-results-and-provides-update
https://www.nasdaq.com/press-release/aprea-therapeutics-to-highlight-changing-treatment-paradigm-in-mds-as-well-as
https://www.nasdaq.com/press-release/aprea-therapeutics-launches-disease-awareness-website-for-healthcare-professionals
https://www.nasdaq.com/press-release/aprea-therapeutics-receives-ok-from-fda-to-initiate-phase-1-clinical-studies-for-next
https://www.nasdaq.com/press-release/aprea-therapeutics-appoints-michael-a.-kelly-to-board-of-directors-2020-09-29
https://www.nasdaq.com/press-release/aprea-therapeutics-promotes-gregory-s.-wessels-to-chief-commercial-officer-and
https://www.nasdaq.com/press-release/aprea-therapeutics-to-present-at-upcoming-investor-conferences-2020-09-03
https://www.nasdaq.com/press-release/aprea-therapeutics-reports-second-quarter-2020-financial-results-and-provides-update
https://www.nasdaq.com/press-release/aprea-therapeutics-announces-expansion-of-clinical-trial-evaluating-eprenetapopt-for
https://www.nasdaq.com/press-release/aprea-therapeutics-appoints-fouad-namouni-m.d.-and-richard-peters-m.d.-ph.d.-to-board
https://www.nasdaq.com/press-release/aprea-therapeutics-completes-full-enrollment-of-phase-3-clinical-trial-in-tp53-mutant
https://www.nasdaq.com/press-release/aprea-therapeutics-to-present-at-2020-rbc-capital-markets-global-healthcare
https://www.nasdaq.com/press-release/aprea-therapeutics-reports-first-quarter-2020-financial-results-and-provides-update
https://www.nasdaq.com/press-release/aprea-therapeutics-launches-new-corporate-website-www.aprea.com-2020-04-06
https://www.nasdaq.com/press-release/aprea-therapeutics-reports-fourth-quarter-and-full-year-2019-financial-results-and
https://www.nasdaq.com/press-release/aprea-therapeutics-appoints-gregory-s.-wessels-as-vice-president-commercial-2020-02
https://www.nasdaq.com/press-release/aprea-therapeutics-receives-fda-breakthrough-therapy-designation-for-apr-246-in
https://www.nasdaq.com/press-release/aprea-therapeutics-to-present-at-the-38th-annual-j.p.-morgan-healthcare-conference-on
